Incorporating bortezomib into the treatment of lung cancer

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume13
Issue number15
DOIs
StatePublished - Aug 1 2007

Fingerprint

Lung Neoplasms
Bronchiolo-Alveolar Adenocarcinoma
Therapeutics
Proteasome Inhibitors
Cytotoxins
Small Cell Lung Carcinoma
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Bortezomib
Radiation
Apoptosis
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incorporating bortezomib into the treatment of lung cancer. / Davies, Angela M.; Lara, Primo N; Mack, Philip; Gandara, David R.

In: Clinical Cancer Research, Vol. 13, No. 15, 01.08.2007.

Research output: Contribution to journalArticle

@article{fa57c486f98649c1b4455f642cfbf4c4,
title = "Incorporating bortezomib into the treatment of lung cancer",
abstract = "Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.",
author = "Davies, {Angela M.} and Lara, {Primo N} and Philip Mack and Gandara, {David R}",
year = "2007",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0334",
language = "English (US)",
volume = "13",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Incorporating bortezomib into the treatment of lung cancer

AU - Davies, Angela M.

AU - Lara, Primo N

AU - Mack, Philip

AU - Gandara, David R

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.

AB - Bortezomib, a small-molecule proteasome inhibitor, has activity in lung cancer both as a single agent and in combination with agents commonly used in lung cancer. The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents in the treatment of lung cancer. In non-small cell lung cancer, bortezomib as a single agent has limited activity but in combination with chemotherapy has shown encouraging activity without significantly adding to toxicity. Bortezomibas a single agent has shown minimal activity in small cell lung cancer. Although the role of bortezomib in lung cancer is uncertain, it is likely to have its greatest clinical benefit when given in combination with other therapeutics. Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=34547692973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547692973&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0334

DO - 10.1158/1078-0432.CCR-07-0334

M3 - Article

C2 - 17671158

AN - SCOPUS:34547692973

VL - 13

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -